SCHEMBL70999

SCHEMBL70999

N#Cc1cccc(NC2CCN(C(=O)CNC(=O)c3cc(-c4ccccc4)[nH]n3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLNR O43193 5/20 0.47
CYP3A4 P08684 1/20 0.47
FAAH O00519 1/20 0.39
P2RY12 Q9H244 3/20 0.39
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
FLT3 P36888 2/20 0.37
CHEK1 O14757 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
CSF1R P07333 1/20 0.37
KIT P10721 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69855 0.86 P2RY12 (0.40) MLNRCYP3A4P2RY12KDM1AMAOA
SCHEMBL70064 0.84 EPHX2 (0.47) P2RY12CPT2CPT1AMGLLCCR3
SCHEMBL70832 0.80 SCD (0.43) P2RY12KIT
SCHEMBL29384715 0.80 P2RY12 (0.44) P2RY12FLT3MAPK1
SCHEMBL70773 0.80 P2RY12 (0.41) P2RY12FLT3
SCHEMBL69043 0.80 P2RY12 (0.44) P2RY12FLT3MAPK1
SCHEMBL69114 0.80 P2RY12 (0.44) P2RY12
SCHEMBL29384862 0.80 P2RY12 (0.44) P2RY12
SCHEMBL69628 0.78 FLT3 (0.41) P2RY12FLT3
SCHEMBL69470 0.78 SCD (0.44) P2RY12FLT3PIM1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP claimed
US-12433880-B2 Methods for the treatment of neurological disorders JANSSEN PHARMACEUTICA NV (BE) 2025-10-07 US disclosed
EP-3566055-B1 SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2025-03-12 EP disclosed
US-20220040167-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2022-02-10 US disclosed
CN-110392833-A The method for treating nervous disorders 优曼尼蒂治疗公司 2019-10-29 CN disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12433880-B2 Methods for the treatment of neurological disorders NLN, CLN6, OTC MLNR 4428/4885CYP3A4 2842/4885FAAH 507/4885
US-20220040167-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NLN, CLN6, OTC MLNR 4428/4885CYP3A4 2842/4885FAAH 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.